secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2021-12-01T23:59:59+00:00
Accession:  0001628280-21-024319
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex appoints Caroline S. Levy to Board, effective December 1, 2021
------------------------------------------------------------------------

- Caroline S. Levy, former Senior Equity Research Analyst at Macquarie Capital, joins ChromaDex Board.
- Ms. Levy appointed to Audit Committee and Nominating and Corporate Governance Committee.
- Annual retainer of $40,000, plus $10,000 (Audit) and $5,000 (Nominating) committee fees.
- Granted option to purchase 40,000 shares vesting over three years; annual meeting options of 20,000 shares.
- Board determined Ms. Levy is independent under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828021024319/0001628280-21-024319-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828021024319/cdxc-20211201.htm
  HTML page:      https://secwatch.observer/filing/0001628280-21-024319

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer